Combined QSAR-based virtual screening and fluorescence binding assay to identify natural product mediators of Interferon Regulatory Factor 7 (IRF-7) in pulmonary infection

SAR and QSAR in Environmental Research

Volumn 27, Issue 11, 2016, Pages 939-948

  Liu, Y ^a   Huang, L ^a   Ye, H ^a   Lv, X ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Interferon regulatory factor 7; natural product; pneumonia; pulmonary infection; quantitative structure activity relationship

Indexed keywords

ANTIBIOTICS; ASSAYS; BINDING ENERGY; DIGITAL LIBRARIES; DISSOCIATION; FLUORESCENCE; GLYCOPROTEINS; HYDROGEN BONDS; IONS; PROTEINS; VAN DER WAALS FORCES;

BINDING ASSAYS; FLUORESCENCE BINDING; INTERFERON REGULATORY FACTOR-7; INTERFERON REGULATORY FACTORS; NATURAL PRODUCTS; PNEUMONIA; PULMONARY INFECTIONS; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP; SCORING FUNCTIONS; VIRTUAL SCREENING;

LIGANDS;

EID: 84992091760     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2016.1243576     Document Type: Article

References (32)

1. R., Lu and P.M., Pitha, Monocyte differentiation to macrophage requires interferon regulatory factor 7, J. Biol. Chem. 276 (2001), pp. 45491–45496.
2. S., Ning, J.S., Pagano, and G.N., Barber, IRF7:Activation, regulation, modification and function, Genes Immun. 12 (2011), pp. 399–414.
3. S., Hippenstiel, B., Opitz, B., Schmeck, and N., Suttorp, Lung epithelium as a sentinel and effector system in pneumonia — molecular mechanisms of pathogen recognition and signal transduction, Respir. Res. 7 (2006), p. 97.
4. M.J., Holtzman, J.W., Tyner, E.Y., Kim, M.S., Lo, A.C., Patel, L.P., Shornick, E., Agapov, and Y., Zhang, Acute and chronic airway responses to viral infection:Implications for asthma and chronic obstructive pulmonary disease, Proc. Am. Thorac. Soc. 2 (2005), pp. 132–140.
5. I., Musmuca, S., Simeoni, A., Caroli, and R., Ragno, Small-molecule interferon inducers. Toward the comprehension of the molecular determinants through ligand-based approaches, J. Chem. Inf. Model. 49 (2009), pp. 1777–1786.
6. F., McNab, K., Mayer-Barber, A., Sher, A., Wack, and A., O'Garra, Type I interferons in infectious disease, Nat. Rev. Immunol. 15 (2015), pp. 87–103.
7. D.J., Newman and G.M., Cragg, Natural products as sources of new drugs over the 30 years from 1981 to 2010, J. Nat. Prod. 75 (2012), pp. 311–335.
8. P.S., Haddad, G.A., Azar, S., Groom, and M., Boivin, Natural health products, modulation of immune function and prevention of chronic diseases, Evid. Based Complement. Alternat. Med. 2 (2005), pp. 513–520.
9. J.E., Talmadge, Natural product derived immune-regulatory agents, Int. Immunopharmacol. 37 (2016), pp. 5–15.
10. O., Obrezanova and M.D., Segall, Gaussian processes for classification:QSAR modeling of ADMET and target activity, J. Chem. Inf. Model. 50 (2010), pp. 1053–1061.
11. L., You, V., Brusic, M., Gallagher, and M., Bodén, Using Gaussian process with test rejection to detect T-cell epitopes in pathogen genomes, IEEE/ACM Trans. Comput. Biol. Bioinform. 7 (2010), pp. 741–751.
12. C.E., Rasmussen and C.K.I., Williams, Gaussian Processes for Machine Learning, MIT Press, MA, 2006.
13. A., Marrel, B., Iooss, F., Van Dorpe, and E., Volkova, An efficient methodology for modeling complex computer codes with Gaussian processes, Comput. Stat. Data Anal. 52 (2008), pp. 4731–4744.
14. P., Zhou, X., Chen, Y., Wu, and Z., Shang, Gaussian process:An alternative approach for QSAM modeling of peptides, Amino Acids 38 (2010), pp. 199–212.
15. P., Wolfe, Convergence conditions for ascent methods, SIAM Rev. 11 (1969), pp. 226–235.
16. R., Wang, X., Fang, Y., Lu, and S., Wang, The PDBbind database:Collection of binding affinities for protein-ligand complexes with known three-dimensional structures, J. Med. Chem. 47 (2004), pp. 2977–2980.
17. H.M., Berman, J., Westbrook, Z., Feng, G., Gilliland, T.N., Bhat, H., Weissig, I.N., Shindyalov, and P.E., Bourne, The protein data bank, Nucleic Acids Res. 28 (2000), pp. 235–242.
18. Y., Cao and L., Li, Improved protein-ligand binding affinity prediction by using a curvature-dependent surface-area model, Bioinformatics 30 (2014), pp. 1674–1680.
19. X., Cheng, Y., Mei, X., Ji, Q., Xue, and D., Chen, Molecular mechanism of the susceptibility difference between HLA-B*27:02/04/05 and HLA-B*27:06/09 to ankylosing spondylitis:Substitution analysis, MD simulation, QSAR modelling, and in vitro assay, SAR QSAR Environ. Res. 27 (2016), pp. 409–425.
20. S., Salentin, S., Schreiber, V.J., Haupt, M.F., Adasme, and M., Schroeder, PLIP:Fully automated protein-ligand interaction profiler, Nucleic Acids Res. 43 (2015), pp. W443–W447.
21. M.F., Sanner, A.J., Olson, and J.C., Spehner, Reduced surface:An efficient way to compute molecular surfaces, Biopolymers 38 (1996), pp. 305–320.
22. M.S., Till and G.M., Ullmann, McVol — a program for calculating protein volumes and identifying cavities by a Monte Carlo algorithm, J. Mol. Model. 16 (2010), pp. 419–429.
23. W.J., Allen, T.E., Balius, S., Mukherjee, S.R., Brozell, D.T., Moustakas, P.T., Lang, D.A., Case, I.D., Kuntz, and R.C., Rizzo, DOCK6:Impact of new features and current docking performance, J. Comput. Chem. 36 (2015), pp. 1132–1156.
24. J.J., Irwin and B.K., Shoichet, ZINC — a free database of commercially available compounds for virtual screening, J. Chem. Inf. Model. 45 (2005), pp. 177–182.
25. P., De Ioannes, C.R., Escalante, and A.K., Aggarwal, Structures of apo IRF-3 and IRF-7 DNA binding domains:Effect of loop L1 on DNA binding, Nucleic Acids Res. 39 (2011), pp. 7300–7307.
26. D., Kozakov, L.E., Grove, D.R., Hall, T., Bohnuud, S.E., Mottarella, L., Luo, B., Xia, D., Beglov, and S., Vajda, The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins, Nat. Protoc. 10 (2015), pp. 733–755.
27. G., Mocz and J.A., Ross, Fluorescence techniques in analysis of protein-ligand interactions, Methods Mol. Biol. 2013 (1008), pp. 169–210.
28. A., Golbraikh and A., Tropsha, Beware of q2!, J. Mol. Graph. Model. 20 (2002), pp. 269–276.
29. A., Tropsha, P., Gramatica, and V.K., Gombar, The importance of being earnest:Validation is the absolute essential for successful application and interpretation of QSPR models, QSAR Comb. Sci. 22 (2003), pp. 69–77.
30. D., Xu and Y., Zhang, Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization, Biophys. J. 101 (2011), pp. 2525–2534.
31. H., Gong, Z., Yuan, and L., Zhan, High-throughput screening against ~6.1 million structurally diverse, lead-like compounds to discover novel ROCK inhibitors for cerebral injury recovery, Mol. Divers. 20 (2016), pp. 537–549.
32. B., Chen, P., Greenside, H., Paik, M., Sirota, D., Hadley, and A.J., Butte, Relating chemical structure to cellular response:An integrative analysis of gene expression, bioactivity, and structural data across 11,000 compounds, CPT Pharmacom. Syst. Pharmacol. 4 (2015), pp. 576–584.